Backed by Eli Lil­ly, a lit­tle-known and se­cre­tive Chi­nese biotech fills the tank as it heads to the clin­ic

A Chi­nese biotech backed by Lil­ly Asia Ven­tures just got some new cash to throw around.

Lynk Phar­ma­ceu­ti­cals pulled in $50 mil­lion in a re­cent­ly com­plet­ed Se­ries B, the biotech an­nounced Fri­day, a lit­tle over three years af­ter launch. The com­pa­ny plans to use the funds to sup­port Phase I and Phase II stud­ies for mul­ti­ple pipeline pro­grams, though it didn’t spec­i­fy for which.

“Since the es­tab­lish­ment of Lynk Phar­ma­ceu­ti­cals, we have been ad­vanc­ing our projects with ef­fi­cient ex­e­cu­tion, and we have made sig­nif­i­cant progress in just three and a half years,” CEO Zhao-Kui Wan said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER